Plasmacytoma relapses in the absence of systemic progression post‐high‐dose therapy for multiple myeloma
Evangelos Terpos(National and Kapodistrian University of Athens), Jane F. Apperley(Hammersmith Hospital), G. L. Scott(Bristol Royal Infirmary), Peter Rose(Academy of Nutrition and Dietetics), Supratik Basu, Diana Samson(Myeloma UK), Katayoun Rezvani(The University of Texas MD Anderson Cancer Center), Alison Milne, Amin Rahemtulla(Hammersmith Hospital)
Cited by 67
Related Papers
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Hydrogen Sulfide and Cell Signaling
|The Annual Review of Pharmacology and Toxicology|2011|1.3k
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
|British Journal of Haematology|2012|867
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493